Newborn Persistent Hypoglycemia Clinical Pathway — N/IICU

Clinical Pathways Home Emergency ICU Inpatient Outpatient Specialty Care Primary Care

Goals and Metrics

Patient Education

Provider Resources

Related Pathway

Glucose Monitoring in the
Healthy Newborn, Inpatient

Newborn with Persistent Hypoglycemia

Glucose < 50 mg/dL from random glucose test or diagnostic fast
- Obtain Critical Fasting Labs
- Then perform Glucagon Stimulation Test
Check Newborn Screen
Consult Endocrinology
Review
- Differential Diagnosis of Persistent Hypoglycemia
- Metabolic Diseases and Endocrine Disorders

Interpretation of Lab Results

Consult Metabolism for
Suspected Metabolic Disease

Suspected Hyperinsulinism

HI Diagnostic criteria when glucose < 50 mg/dL
- Detectable insulin > 2 mIU/mL
- Low beta-hydroxybutyrate < 1.8 mmol/L
- Low free fatty acids < 1.7 mmol/L

Etiologies of HI
Medications: Diazoxide, Glucagon infusion
Additional Evaluation Considerations
- Genetic Consultation, genetic testing
- Cardiology Consultation

Treatment:
- 5 Day Trial of Diazoxide
- Start chlorothiazide
Treatment Goal:
- Maintain euglycemia, glucose > 70 mg/dL for infants > 72 hrs of life

Fasting Test
- On Diazoxide off IVF
- Goal: Fasting time 6-12 hrs with plasma glucose maintained > 70

Fails Fast

Tolerates Fast

Diazoxide unresponsiveness suggests a K_ATP channel HI and potential surgical candidate
Send expedited genetic testing of ABCC8 and KCNJ11
Discontinue diazoxide
Maintain plasma glucose above 70 mg/dL with dextrose containing IVF
Consider central line placement to give higher dextrose concentration in IVF
Consider continuous glucagon infusion (1 mg/day) if fluid overload is a concern
Arrange transfer to CHOP for further care
and potential 18F-DOPA PET

Continue diazoxide with glucose monitoring
Obtain ECHO, CBC with diff, and BMP 1 week after starting diazoxide or prior to discharge
Send comprehensive HI genetic testing
Discharge Planning with Endocrinology

Posted: September 2016
Revised: May 2023

Authors:
- D. De León, MD;
- C. Stanley, MD;
- R. Simmons, MD;
- K. Wade, MD;
- C. Ficicioglu, MD;
- K. Lord, MD;
- S. Ghavam, MD;
- A. Bustin, PharmD;
- S. Gattoline, PharmD

Editors: Clinical Pathways Team

Evidence

CHOP Program

Congenital Hyperinsulinism Center

If you have questions about any of the clinical pathways or about the process of creating a clinical pathway please contact us.

©2024 by Children's Hospital of Philadelphia, all rights reserved.
Use of this site is subject to the Terms of Use.

The clinical pathways are based upon publicly available medical evidence and/or a consensus of medical practitioners at The Children’s Hospital of Philadelphia (“CHOP”) and are current at the time of publication. These clinical pathways are intended to be a guide for practitioners and may need to be adapted for each specific patient based on the practitioner’s professional judgment, consideration of any unique circumstances, the needs of each patient and their family, and/or the availability of various resources at the health care institution where the patient is located.

Accordingly, these clinical pathways are not intended to constitute medical advice or treatment, or to create a doctor-patient relationship between/among The Children’s Hospital of Philadelphia (“CHOP”), its physicians and the individual patients in question. CHOP does not represent or warrant that the clinical pathways are in every respect accurate or complete, or that one or more of them apply to a particular patient or medical condition. CHOP is not responsible for any errors or omissions in the clinical pathways, or for any outcomes a patient might experience where a clinician consulted one or more such pathways in connection with providing care for that patient.

N/IICU Clinical Pathway for Evaluation/Treatmentof Persistent Hypoglycemia in the Newborn

Evidence

CHOP Program

N/IICU Clinical Pathway for Evaluation/Treatment
of Persistent Hypoglycemia in the Newborn